SCHEMBL290724

SCHEMBL290724

C[CH]c1scnc1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20604223 0.81
SCHEMBL9994026 0.81
SCHEMBL347422 0.78
SCHEMBL6051551 0.78
SCHEMBL363540 0.78
Hydrogen Sulfide SCHEMBL28240009 0.76
Bromide SCHEMBL4189993 0.76
SCHEMBL2734750 0.76 KDM4E (0.34)
SCHEMBL23457271 0.73
SCHEMBL16072793 0.73 KDM4E (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1073428-B1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES CHOONGWAE PHARMA CO LTD (KR) 2004-10-27 EP claimed
WO-2002040449-A1 DIHYDROISOQUINOLINES AS NOVEL PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO claimed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 WO disclosed
EP-4275752-A2 TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS Omeros Corporation (US) 2023-11-15 EP disclosed
US-20230110784-A1 TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS OMEROS CORPORATION 2023-04-13 US disclosed
CN-115192711-A Use of PDE7 inhibitors for the treatment of movement disorders 奥默罗斯公司 2022-10-18 CN disclosed
CN-114984229-A Treatment of addiction and impulse control disorders using PDE7 inhibitors 奥默罗斯公司 2022-09-02 CN disclosed
US-11207275-B2 Treatment of addiction and impulse-control disorders using PDE7 inhibitors OMEROS CORPORATION (US) 2021-12-28 US disclosed
CN-112168972-A Treatment of addiction and impulse control disorders using PDE7 inhibitors 奥默罗斯公司 2021-01-05 CN disclosed
CN-104758291-B Use of PDE7 inhibitors for the treatment of movement disorders 奥默罗斯公司 2020-03-03 CN disclosed
US-20190183824-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS OMEROS CORPORATION 2019-06-20 US disclosed
US-6693126-B2 OXIME-SUBSTITUTED M-DIHYDROXYBENZENE OR 1,3-BENZODIOXOLE COMPOUND OF GIVEN FORMULA AND AN INERT CARRIER CHOONGWAE PHARM. CO., LTD. (KR) 2004-02-17 US disclosed
US-20030083326-A1 Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases CHOONGWAE PHARM. CO., LTD. (KR) 2003-05-01 US disclosed
US-6469003-B1 COMPOUNDS HAVING CELL ADHESION INHIBITING ACTIVITY NIHON NOHYAKU CO., LTD. (JP) 2002-10-22 US disclosed
WO-2002040449-A1 DIHYDROISOQUINOLINES AS NOVEL PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed
EP-1130015-A1 PYRIDAZINONE DERIVATIVES Nihon Nohyaku Co., Ltd. (JP) 2001-09-05 EP disclosed
EP-1073428-A1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES Choongwae Pharma Co., Ltd. (KR) 2001-02-07 EP disclosed
WO-1999055318-A1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES CHOONGWAE PHARM. CO., LTD. (KR) 1999-11-04 WO disclosed
US-5389663-A Fungicides TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-02-14 US disclosed
EP-0510700-A2 Azole compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-10-28 EP disclosed